- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT04492956
성인 말더듬(자유롭게 말하기)에서 에코피팜 또는 위약의 효과
소아기에 발병하는 유창성 장애(말더듬)가 있는 성인에서 에코피팜 정제의 효능 및 안전성을 평가하기 위한 다기관, 무작위, 이중 맹검, 위약 대조, 병렬 그룹, 2상 탐색적 연구
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, Phase 2 exploratory study in adult subjects with childhood onset fluency disorder.
연구 개요
상세 설명
At the Baseline visit, eligible subjects will be randomized 1:1 to receive either a target steady-state dose of ecopipam HCl ~2 mg/kg/day or matching placebo for a 12-week Treatment Period consisting of a 4-week Titration Phase followed by an 8-week Maintenance Phase.
Subjects will return to the clinic at 4, 8, and 12 weeks after Randomization and Follow-up visits 7 and 14 days after completing the Treatment Period or Early Discontinuation. Efficacy assessments will be conducted at Weeks 4, 8, and 12 and safety assessments will be conducted at all visits. Subjects will have adverse events and other safety parameters assessed by phone or video conference at Weeks 2, 6 and 10 and 30 days after the last study drug administration. Signs or symptoms of withdrawal, abuse, and dependence will be monitored throughout the study.
At the end of the Treatment Period or Early Discontinuation, subjects will taper study drug by 25 mg/day until off study drug, for up to 1 week.
연구 유형
등록 (실제)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
California
-
Riverside, California, 미국, 92501
- UC Riverside
-
Santa Ana, California, 미국, 92705
- CI Trials
-
-
Florida
-
Jacksonville, Florida, 미국, 32256
- Clinical Neuroscience Solutions Inc
-
Orlando, Florida, 미국, 32801
- Clinical Neuroscience Solutions Inc
-
-
Georgia
-
Atlanta, Georgia, 미국, 30341
- Institute For Advanced Medical Research
-
-
Kansas
-
Prairie Village, Kansas, 미국, 66208
- Social Psychiatry Research Institute
-
-
Michigan
-
East Lansing, Michigan, 미국, 48824
- Michigan State University
-
-
New York
-
Brooklyn, New York, 미국, 11235
- Social Psychiatry Research Institute
-
-
Tennessee
-
Memphis, Tennessee, 미국, 38119
- Clinical Neuroscience Solutions Inc
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Able to read and write in English and provide informed consent
- 18 years or older of age at screening
- Weighs >= 45 kg (~99 lbs)
- Satisfies DSM-5 criteria for childhood onset fluency disorder
- History of stuttering for >=2 years with onset consistent to developmental in nature
- Must meet an allowed severity of stuttering at screening and baseline, scored by a central rater
- Completed an adequate course of speech therapy
- Has a qualifying IOS or Android smartphone
- Must discontinue all medications used to treat stuttering for at least 14 days prior to screening
- Sexually active females of child bearing potential must be using effective contraception during and 30 days after participation
- Sexually active males must use a double barrier method of contraception during and 30 days after participation
Exclusion Criteria:
- Stuttering is related to a known neurological cause
- Initiation of new behavioral therapies for stuttering within 10 weeks prior to baseline
- Unstable medical illness or clinically significant abnormalities on screening tests/exams
- At a significant risk of committing suicide
- Are pregnant or lactating
- Positive urine drug screen
- Lifetime history of major depressive episode
- History of seizures
- Have been previously treated with ecopipam
- Unstable use of medications prior to screening
- Use of prohibited medications or need for medications which would have unfavorable interactions with ecopipam
- Not suitable for study in the opinion of the Principle Investigator
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Ecopipam HCl ~2mg/kg/day
Ecopipam HCl tablets of 12.5, 50, and 75 mg for daily, oral administration for 12 weeks |
Oral tablet |
|
위약 비교기: Matching Placebo
Matching placebo tablets for daily, oral administration for 12 weeks |
Oral tablet |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Stuttering Severity Instrument, 4th Edition (SSI-4)
기간: 12 weeks
|
The SSI-4 is a reliable and valid norm-referenced stuttering assessment that can be used for both clinical and research purposes. It takes 15-20 minutes to complete. It measures stuttering severity in both children and adults in the 4 areas of speech behavior:1. frequency 2. duration 3. physical concomitants 4. naturalness of the individual's speech. Frequency is expressed in percent of syllables stuttered and is converted to scale scores of 2-18. Duration is timed to the nearest one tenth of a second and is converted to scale scores of 2-18. The 4 types of physical concomitants are converted to scale scores of 0-56. |
12 weeks
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Clinical Global Impression - Severity (CGI-S) Baseline to Week 12
기간: Baseline, Week 4, Week 8 and 12 weeks
|
The CGI consists of two reliable and valid 7-item Likert scales used to assess severity and change in clinical symptoms. The severity scale (CGI-S) ranges from 1 (Normal, not ill) to 7 (extremely ill). Pediatric and adult versions of the CGI-TS-S and CGI-TS-I scales are available and will be administered according to the age of the subject at the time of Informed Consent. The efforts of peers, teachers and parents to assist, accommodate, or support the subject should be considered in overall severity in the case of pediatric subjects. |
Baseline, Week 4, Week 8 and 12 weeks
|
|
Change From Baseline Subjective Screening of Stuttering (SSS)
기간: From baseline (enrollment) to Week 12.
|
The Subjective Screening of Stuttering (SSS) research edition is designed to quantify the selected self-reports of people who stutter prior to, during, and following their treatment. The three areas screened by the SSS are perceived stuttering severity (range 3-27), the locus of control subtest (range 6-54), and reported word or situation avoidance (range 6-54). Each of the areas has two or three items rated for three audiences on a 1 to 9, equal appearing scale in which 1 represents "normal" or target level and 9 is the most severe. The total score has a range of 15-135. Higher scores indicate greater severity. |
From baseline (enrollment) to Week 12.
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Atul R Mahableshwarkar, MD, DFAPA, Emalex Biosciences Inc.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .